Taiwan Liposome Company, Ltd. announced that preparations for pivotal studies of TLC590 for postsurgical pain management are underway, with planned End-of-Phase-2 meetings to occur in 2021 with the United States Food and Drug Administration (FDA) on the design of the clinical trials and production preparations.